Skip to search formSkip to main contentSkip to account menu

alemtuzumab Injection [Lemtrada]

National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

1.2 ML alemtuzumab 10 MG/ML Injection [Lemtrada]
InjectionLemtrada

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Towards a More User-Friendly Medication Information Delivery to People Living with Multiple Sclerosis: A Case Study with Alemtuzumab.
Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system which leads to demyelination and neurodegeneration… 
2019
2019
Alemtuzumab (Lemtrada®): nuevas restricciones de uso
Tras finalizar la evaluacion europea del balance beneficio-riesgo de alemtuzumab (Lemtrada®) se recomienda restringir la… 
2019
2019
Alemtuzumab (Lemtrada®): restricciones de uso provisionales por motivos de seguridad
La gravedad de los casos identificados ha motivado el inicio de una revisión detallada de la información disponible a nivel… 
2017
2017
Multiple Sclerosis Selective Targeting of T and B Cell Populations by Alemtuzumab in the Treatment of Multiple Sclerosis
U pstream targeting of both T and B cells is a rational therapeutic approach in multiple sclerosis (MS) in view of how both cell… 
2016
2016
ALAIN01—Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential
BackgroundAlemtuzumab (Lemtrada®) is a newly approved therapeutic agent for relapsing-remitting multiple sclerosis (RRMS). In… 
2016
2016
Other Approved Therapeutic Monoclonal Antibodies
Twenty-four approved monoclonal antibodies (mAbs) not indicated for cancer therapy are specific for a total of 20 different… 
2015
2015
Treatment Effects Maintained Over Five Years in Majority of Patients with Relapsing Remitting Multiple Sclerosis who Received Genzyme’s Lemtrada® (alemtuzumab) in Clinical Trials
  • 2015
  • Corpus ID: 58898003
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company, today announced posit ive new five-year investigational data from… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)